New Hampshire Patent of the Month – May 2025
Avitide LLC has secured a patent for a breakthrough that could accelerate the manufacturing of life-changing gene therapies. U.S. Patent No. 12312607, titled ‘AAV9 affinity agents’, introduces novel purification agents designed to isolate AAV9—one of the most widely used viral vectors in gene therapy—with greater speed and precision. The innovation aims to reduce bottlenecks in the production of genetic treatments targeting diseases like spinal muscular atrophy and neurological disorders.
Streamlining Biomanufacturing
The new affinity agents target AAV9 with high specificity, enabling cleaner and more efficient capture of the viral vector during purification. This advancement can reduce processing steps and increase consistency—critical factors as gene therapy scales from clinical trials to commercial use. By minimizing impurities and yield loss, the technology promises better batch reliability and lower production costs.
Real-World Therapeutic Impact
AAV9 is a preferred delivery system for genetic material due to its ability to cross the blood-brain barrier. But purifying it at scale has remained a technical challenge. This patent addresses that hurdle with a novel set of ligands optimized for AAV9 capture, supporting faster, safer, and more accessible gene therapy development. It could also ease regulatory approvals by improving product consistency.
Innovation in the Pipeline
This development marks another step forward for Avitide LLC, a company focused on advanced bioprocessing solutions. As gene therapy continues its rapid evolution, platform technologies like this offer a powerful edge in making treatments more broadly available—especially for rare and currently untreatable conditions.
Learn More:
Are you developing new or improved products, or thinking of applying for a patent? Did you know your research work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? To find out more, please check out our free online eligibility test.
Feel free to book a quick teleconference with one of R&D Tax specialists if you would like to learn more about R&D Tax Credit opportunities.
Who We Are:
Swanson Reed is one of the largest Specialist R&D Tax Credit advisory firm in the United States. With offices nationwide, we are one of the only firms globally to exclusively provide R&D Tax Credit consulting services to our clients. We have been exclusively providing R&D Tax Credit claim preparation and audit compliance solutions for over 30 years.
Swanson Reed’s New Hampshire office provides R&D tax credit consulting and advisory services to Manchester, Nashua, Concord, Derry, and Dover.
Swanson Reed hosts daily free webinars and provides free IRS CE and CPE credits for CPAs. For more information please click here or contact your usual Swanson Reed representative.
